TOKYO & WALTHAM, Mass.--(BUSINESS WIRE)--Modalis Therapeutics Corporation (Tokyo Stock Exchange: 4883), a pioneering company developing innovative products for the treatment of rare genetic diseases ...
RENO, NV, UNITED STATES, April 9, 2025 /EINPresswire.com/ -- Sarcomatrix Therapeutics, a privately held biopharmaceutical company advancing transformative therapies ...
The renewal highlights ongoing progress in developing rhLAM-111 for rare muscular diseases, with a new emphasis on Duchenne Muscular Dystrophy. We are excited to have renewed our EU Orphan Drug ...
Hosted on MSN
Muscle regeneration hindered by missing protein in rare muscular dystrophy, study shows
For more than two decades, researchers at the University of Basel, Switzerland, have been investigating a severe form of muscular dystrophy in which muscles progressively degenerate. The research team ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results